European healthcare contract development and manufacturing organization (CDMO) market was valued at $45.6 billion in 2025 and is growing at a CAGR of 4.9% during the forecast period (2026-2035). The European healthcare contract development and manufacturing organization (CDMO) market is experiencing steady growth as pharmaceutical and biotechnology companies increasingly rely on specialized partners to streamline development and manufacturing processes. Rising demand for biologics, advanced therapies, and complex small-molecule drugs is driving outsourcing to CDMOs with strong regulatory expertise and scalable capabilities. Companies are focusing on integrated service models that cover development, analytical testing, and commercial manufacturing to reduce time-to-market and ensure compliance with stringent European regulations. Technological adoption, including automation, digital quality systems, and advanced process monitoring, is improving efficiency and consistency across production stages. Regional CDMOs are also investing in capacity expansion and facility modernization to accommodate diverse therapeutic portfolios. Collectively, these trends indicate a market shaped by innovation, operational resilience, and increasing strategic partnerships.
Browse the full report description of “European Healthcare Contract Development and Manufacturing Organization (CDMO) Market Size, Share & Trends Analysis Report by Services (Contract Development and Contract Manufacturing) and Forecast Period 2026-2035” of https://www.omrglobal.com/industry-reports/europe-healthcare-cdmo-market
Rising Regulatory Approvals Accelerate Outsourcing Momentum
The European pharmaceutical landscape is witnessing significant innovation, with a growing pipeline of complex therapies advancing toward commercialization. Manufacturers are increasingly turning to specialized external partners to leverage expertise and scale in development and production. The rise of advanced biologics and novel treatments is driving the need for flexible, adaptable manufacturing capabilities. CDMOs play a central role by supporting development, ensuring regulatory readiness, and managing commercial-scale production. This collaborative approach enables faster market entry and enhances operational efficiency across the region. Collectively, these dynamics are reinforcing sustained growth in the European healthcare CDMO market.
European Healthcare CDMO Market Key Players
The key players in the healthcare CDMO market are Lonza Group AG, Thermo Fisher Scientific Inc., WuXi Biologics Co., Ltd., Siegfried Holding AG, and Eurofins Scientific SE, among others. These companies collectively provide a wide range of services across the pharmaceutical and biotechnology value chain, supporting development, scale-up, and commercial manufacturing activities. The market is increasingly characterized by long-term strategic partnerships, where reliability, flexibility, and scalability are critical differentiators. Growing demand for complex therapies and biologics further reinforces the importance of experienced CDMO partners in enabling timely and efficient drug development and commercialization.
Market Coverage
Key questions addressed by the report.
European Healthcare CDMO Market Report Segment
By Services
European Healthcare CDMO Market Report Segment by Country
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/europe-healthcare-cdmo-market